TRACK-TBI, a collaborative research consortium that is supported by One Mind, recently received a major funding award from the U.S. Army Medical Material Development Activity. The $26.2 million award will enable the TRACK-TBI consortium, which is led by the University of California, San Francisco and comprises 18 hospitals with Level 1 trauma centers, to serve as an efficient platform for conducting phase II clinical trials of promising treatments for traumatic brain injury. Proven effective treatments are urgently needed, as to date not a single drug or device has been approved by the FDA for the treatment of acute traumatic brain injury.
Leveraging the advances the TRACK-TBI program has already made that include two Letters of Support from the FDA for their research on imaging and blood biomarkers, the Phase II clinical trials will also incorporate new methodologies in their trial designs, such as adaptive trials and personalized medicine approaches.
“To benefit the 2.5 million Americans who suffer a traumatic brain injury each year and the millions more worldwide, we are proud to support TRACK-TBI. As demonstrated, the TRACK-TBI consortium is positioned to truly accelerate the development of the first meaningful treatments for TBI”, states One Mind President, Brandon Staglin. “The medications that could be developed through TRACK-TBI’s work could significantly improve the quality of life for those impacted by a TBI.”
Read more about One Mind’s support of the TRACK-TBI consortium here.